We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
EFFICACY AND SAFETY OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME.
- Authors
Frustaci, A. M.; Montillo, M.; Rossi, D.; Zinzani, P. L.; Motta, M.; Gaidano, G.; Quaresmini, G.; Scarfò, L.; Pietrasanta, D.; Coscia, M.; Deodato, M.; Zamprogna, G.; Cairoli, R.; Stüssi, G.; Zucca, E.; Pileri, S.; Zenz, T.; Tedeschi, A.
- Abstract
RS mutation profile was tested on pre-treatment cell free DNA. Rate of unmeasurable MRD and impact of mutations and chronic lymphocytic leukemia-RS clonal relation on outcomes will be presented at the meeting. B Introduction: b Chemoimmunotherapy is the standard first line treatment of diffuse large B-cell lymphoma (DLBCL) variant of Richter syndrome (RS).
- Subjects
RICHTER syndrome; ATEZOLIZUMAB; VENETOCLAX; DIFFUSE large B-cell lymphomas; DNA repair
- Publication
Hematological Oncology, 2023, Vol 41, p62
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_27